… on the extent to which immunotherapies must be continued, … the novel coronavirus and the
approved immunotherapies for … but also the potential of immunotherapies to treat COVID-19. …

… ) against SARS-CoV-2 was approved for passive immunotherapy … against SARS-CoV-2 and
its rapidly emerging variants. … mAbs production since the discovery of mAbs [12]. Currently, 8 …

… acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in … ligand, has never been shown
in the context of SARS-CoV-2. … the spike (S) glycoproteins of SARS-CoV-2 and CCCs at the …

… (NAb) responses to SARS-CoV-2 could facilitate vaccine design and drug discovery. Spike
(S) … , when selective pressure is applied in immunotherapies, resulting in resistance against …

… targeting this cytokine in patients with SARS CoV-2 induced disease. We also have a
discussion over IL-6 roles in patients with SARS CoV-2 induced disease who also have cancer. …

Background The COVID-19 pandemic challenges neurologists in counselling patients with
multiple sclerosis (pwMS) regarding their risk by SARS-CoV-2 and in guiding disease-…

… This important discovery represents a major insight into the separate, distinct mechanism in
… in severe disease cases could not protect against SARS-CoV-2 infection, rather aggravating …

… of SARS-CoV‑2 [23]. Recent data further demonstrated that these patients had a reduced
humoral immune response after standard SARS-CoV… vaccination against SARS-CoV‑2 [26, 27]. …

… ‐2, which might play roles in the initiation of SARS‐CoV‐2 … T cell response similar to that of
SARS‐CoV‐2 infection. Moreover, the … new vaccine targets to prevent SARS‐CoV‐2 infection. …

… The discovery of a novel infectious agent from the Coronaviridae family was made possible
… SARS-CoV-2 is a member of the coronavirus family, a large and diverse group of viruses …